Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses: 2022-2024

Historic Operating Expenses for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $348.4 million.

  • Day One Biopharmaceuticals' Operating Expenses fell 0.12% to $64.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.3 million, marking a year-over-year decrease of 4.50%. This contributed to the annual value of $348.4 million for FY2024, which is 69.09% up from last year.
  • Day One Biopharmaceuticals' Operating Expenses amounted to $348.4 million in FY2024, which was up 69.09% from $206.1 million recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Operating Expenses high stood at $348.4 million for FY2024, and its period low was $146.9 million during FY2022.
  • Over the past 3 years, Day One Biopharmaceuticals' median Operating Expenses value was $206.1 million (recorded in 2023), while the average stood at $233.8 million.
  • Data for Day One Biopharmaceuticals' Operating Expenses shows a peak YoY soared of 69.09% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Operating Expenses stood at $146.9 million in 2022, then soared by 40.27% to $206.1 million in 2023, then spiked by 69.09% to $348.4 million in 2024.